Kestra Investment Management LLC Takes $603,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Kestra Investment Management LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,708 shares of the biotechnology company’s stock, valued at approximately $603,000.

Other large investors also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics in the fourth quarter worth $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in United Therapeutics in the third quarter worth $82,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in United Therapeutics in the third quarter worth $90,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 121,864 shares of company stock valued at $44,516,965 over the last three months. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Trading Up 0.6 %

Shares of UTHR opened at $372.83 on Wednesday. The firm has a market capitalization of $16.65 billion, a P/E ratio of 16.37, a P/E/G ratio of 0.96 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $213.75 and a 12-month high of $417.82. The firm has a fifty day moving average price of $362.21 and a 200-day moving average price of $359.74.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.